Payers are strongly reluctant to value surrogate endpoints (SEP) as they carry substantial uncertainty on the final endpoint. However, it seems that SEP are common in payment for performance (P4P) agreements. The objective of this project was to Identify the proportion of SEP used in P4P and coverage with evidence development (CED).